Cancer Cell Therapy Trials Spike in Last Six Months, New Report Finds – Regulatory Focus
Regulatory Focus |
Cancer Cell Therapy Trials Spike in Last Six Months, New Report Finds
Regulatory Focus And three cell and gene therapies have won FDA approval: two Car–T cell therapies, including Novartis' Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL) and Gilead's Yescarta … CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the … |
